Respiratory Function Monitoring

Introduction to Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease that requires a comprehensive management approach, as recommended by the American Thoracic Society and European Respiratory Society 1, 2
IPF is defined as a specific type of chronic and progressive lung disease characterized by a histological and/or radiological pattern of usual interstitial pneumonia, as recommended by the American Thoracic Society and European Respiratory Society 1, 2

Diagnosis of IPF requires exclusion of other known causes of interstitial lung disease (ILD), abnormal pulmonary function tests, characteristic high-resolution computed tomography (HRCT) findings, and in some cases, surgical lung biopsy, as recommended by the American Thoracic Society and European Respiratory Society 3, 4, 1
Initial evaluation should include assessment of symptoms, pulmonary function tests, such as forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO), oxygen saturation at the end of a 6-minute walk test, and extent of honeycombing on HRCT, as well as signs of pulmonary hypertension on echocardiography, as recommended by the European Respiratory Society 2

Regular monitoring of respiratory function parameters is essential to detect potential disease progression, as recommended by the American Thoracic Society 5
A significant decline in lung function, indicated by an absolute decrease in FVC ≥10% or DLCO ≥15%, suggests disease progression 5
The average rate of FVC decline in patients with idiopathic pulmonary fibrosis is 0.2 liters per year, with significant interindividual variability 5
Pulmonary function tests should be performed every 4-6 months or sooner if clinically indicated in patients with IPF, as recommended by the American College of Chest Physicians 1
HRCT should be performed annually if there is suspicion of worsening or risk of lung cancer in patients with IPF, as recommended by the European Respiratory Society 1

Antifibrotic therapy with nintedanib or pirfenidone is recommended as first-line pharmacological treatment to slow disease progression and improve mortality outcomes in patients with IPF, as recommended by the American Thoracic Society and European Respiratory Society 1, 6, 2
Nintedanib, at a dose of 150mg twice daily, reduces FVC decline by 44-57% in IPF patients, as recommended by the American Thoracic Society and European Respiratory Society 1, 6
Pirfenidone, titrated to full dose, reduces FVC decline by 44-57% in IPF patients, as recommended by the American Thoracic Society and European Respiratory Society 6, 2
The American Thoracic Society and European Respiratory Society recommend against combination therapy with prednisone, azathioprine, and N-acetylcysteine in IPF patients due to increased mortality risk, as recommended by the American Thoracic Society and European Respiratory Society 6, 2
Corticosteroids should not be used routinely in IPF, as they have not been shown to improve survival and are associated with substantial morbidity, especially in older patients, as recommended by the American Thoracic Society 4

Targeted cough management may include a trial of inhaled ipratropium, gabapentin for refractory chronic cough, and speech pathology therapy, as recommended by the American College of Chest Physicians 7, 8
Opiates may be recommended for symptom control in persistent, troublesome cough that significantly impacts quality of life, with reassessment at 1 week and monthly thereafter, as suggested by the American Academy of Hospice and Palliative Medicine 8
Early integration of palliative care is recommended for symptom management, focusing on reducing symptoms and providing comfort, as suggested by the European Respiratory Review and American College of Veterinary Internal Medicine 5, 4

Pulmonary rehabilitation programs, including exercise training, should be considered to improve exercise capacity and quality of life in patients with IPF, although it may not be feasible in patients with advanced disease, as recommended by the European Respiratory Society 2
Oxygen therapy, including long-term oxygen therapy and ambulatory oxygen therapy, should be considered for patients with clinically significant resting hypoxemia or exercise desaturation, as recommended by the American Thoracic Society and European Respiratory Review 4, 2, 5

Vaccination against influenza and pneumococcus is recommended for patients with respiratory disease, according to the European Respiratory Society 2
Annual influenza vaccination and pneumococcal vaccination are recommended, as recommended by the European Respiratory Society 2
Lung transplantation should be considered in all patients with definite IPF under the age of 65 years if the disease is severe or worsening, and that patients should be evaluated early in a lung transplant center, as recommended by the American Thoracic Society 2
Patients with IPF should undergo preoperative assessment, including pulmonary function tests (PFTs) with FVC and DLCO measurements, to determine disease severity and identify high-risk patients (FVC <50% or DLCO <30%), as recommended by the American Journal of Respiratory and Critical Care Medicine 5
Evaluate for pulmonary hypertension, as it significantly increases perioperative risk, and implement a prehabilitation program for high-risk patients, including pulmonary rehabilitation exercises, nutritional assessment, and correction of deficiencies, as recommended by the American Journal of Respiratory and Critical Care Medicine and European Respiratory Review 5, 9